CN110770236B - Vmat2抑制剂化合物及其组合物 - Google Patents

Vmat2抑制剂化合物及其组合物 Download PDF

Info

Publication number
CN110770236B
CN110770236B CN201880040884.XA CN201880040884A CN110770236B CN 110770236 B CN110770236 B CN 110770236B CN 201880040884 A CN201880040884 A CN 201880040884A CN 110770236 B CN110770236 B CN 110770236B
Authority
CN
China
Prior art keywords
compound
methyl
group
pharmaceutically acceptable
isoquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880040884.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110770236A (zh
Inventor
尼科尔·哈里奥特
唐纳德·赫廷格
肖恩·布拉努姆
杰弗里·C·卡尔亨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110770236(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CN110770236A publication Critical patent/CN110770236A/zh
Application granted granted Critical
Publication of CN110770236B publication Critical patent/CN110770236B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880040884.XA 2017-04-19 2018-04-17 Vmat2抑制剂化合物及其组合物 Active CN110770236B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US62/487,413 2017-04-19
US201862652837P 2018-04-04 2018-04-04
US62/652,837 2018-04-04
PCT/US2018/028031 WO2018195121A1 (en) 2017-04-19 2018-04-17 Vmat2 inhibitor compounds and compositions thereof

Publications (2)

Publication Number Publication Date
CN110770236A CN110770236A (zh) 2020-02-07
CN110770236B true CN110770236B (zh) 2023-03-24

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040884.XA Active CN110770236B (zh) 2017-04-19 2018-04-17 Vmat2抑制剂化合物及其组合物

Country Status (17)

Country Link
US (1) US11040970B2 (enExample)
EP (1) EP3612532B1 (enExample)
JP (1) JP7170662B2 (enExample)
KR (1) KR20190140968A (enExample)
CN (1) CN110770236B (enExample)
AU (1) AU2018254429A1 (enExample)
BR (1) BR112019021853A2 (enExample)
CA (1) CA3060251A1 (enExample)
CL (1) CL2019002919A1 (enExample)
CO (1) CO2019011604A2 (enExample)
ES (1) ES2971230T3 (enExample)
JO (1) JOP20190239A1 (enExample)
MA (1) MA50145A (enExample)
MX (1) MX2019012336A (enExample)
PE (1) PE20191784A1 (enExample)
TW (1) TW201841913A (enExample)
WO (1) WO2018195121A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY203491A (en) 2017-01-27 2024-06-30 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
PL3684333T3 (pl) 2017-09-21 2025-06-23 Neurocrine Biosciences, Inc. Formulacja walbenazyny o wysokiej dawce oraz kompozycje, sposoby i zestawy z nią związane
KR20250110361A (ko) 2017-10-10 2025-07-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MX2020013004A (es) * 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
MX2021001017A (es) 2018-08-15 2021-04-19 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2).
TW202033521A (zh) * 2018-10-24 2020-09-16 美商紐羅克里生物科學有限公司 製備囊泡單胺轉運蛋白2(vmat2)抑制劑之方法
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
RS67052B1 (sr) 2021-03-22 2025-08-29 Neurocrine Biosciences Inc Vmat2 inhibitori i postupci primene
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
US20250064990A1 (en) 2021-08-20 2025-02-27 Neurocrine Biosciences, Inc. Methods of screening for vmat2 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553487A (zh) * 2006-11-08 2009-10-07 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
WO2016127133A1 (en) * 2015-02-06 2016-08-11 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
ES2327740T3 (es) 2003-06-20 2009-11-03 F. Hoffmann-La Roche Ag Hexahidropiridoisoquinolinas como inhibidoras de la dpp-iv.
JP2008509925A (ja) * 2004-08-13 2008-04-03 オメロス コーポレイション 新規のセロトニンレセプターリガンドおよびそれらの使用
FR2912145B1 (fr) 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2009126305A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University Glucose metabolism modulating compounds
LT3061760T (lt) 2008-09-18 2018-02-26 Auspex Pharmaceuticals, Inc. Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai
US8772301B2 (en) * 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2014043866A1 (zh) 2012-09-19 2014-03-27 中国科学院福建物质结构研究所 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途
US9782398B2 (en) 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
MY197501A (en) 2016-12-22 2023-06-19 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
KR102696516B1 (ko) 2016-12-22 2024-08-22 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553487A (zh) * 2006-11-08 2009-10-07 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
WO2016127133A1 (en) * 2015-02-06 2016-08-11 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis of Bioactive 2-Aza-Analogues of Ipecac and Alangium Alkaloids;Koelzer, Michael;《ChemMedChem》;20101231;第5卷(第9期);1456-1464页 *

Also Published As

Publication number Publication date
EP3612532C0 (en) 2023-12-13
JP2020517607A (ja) 2020-06-18
EP3612532B1 (en) 2023-12-13
US11040970B2 (en) 2021-06-22
CL2019002919A1 (es) 2020-01-17
MA50145A (fr) 2020-07-29
WO2018195121A1 (en) 2018-10-25
CN110770236A (zh) 2020-02-07
MX2019012336A (es) 2020-07-14
BR112019021853A2 (pt) 2020-05-26
KR20190140968A (ko) 2019-12-20
ES2971230T3 (es) 2024-06-04
US20200131173A1 (en) 2020-04-30
AU2018254429A1 (en) 2019-11-07
JP7170662B2 (ja) 2022-11-14
TW201841913A (zh) 2018-12-01
EP3612532A1 (en) 2020-02-26
PE20191784A1 (es) 2019-12-24
CA3060251A1 (en) 2018-10-25
CO2019011604A2 (es) 2019-10-31
JOP20190239A1 (ar) 2019-10-09

Similar Documents

Publication Publication Date Title
CN110770236B (zh) Vmat2抑制剂化合物及其组合物
JP7155206B2 (ja) 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
JP7107950B2 (ja) 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024114905A (ja) Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法
TW202345829A (zh) 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
HK40049687A (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
BR112017027839B1 (pt) Uso de inibidores de vmat2 para preparação de uma composição farmacêutica para tratar mania em um transtorno de humor em um indivíduo; e/ou tratar transtorno obsessivo-compulsivo (toc) refratário ao tratamento
HK1248116B (en) Vmat2 inhibitors for treating neurological diseases or disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant